Neogen Chemicals Limited has informed the Exchange about Transcript of Earnings call held on August 4, 2025.
NEOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neogen Chemicals posted Q1 FY26 revenue of INR 186.7 crore, up 4% year-on-year, despite the Dahej plant being unavailable all quarter due to the fire incident. Organic revenue grew 16% to INR 165 crore while Neogen Ionics contributed INR 5.4 crore. EBITDA was INR 31.5 crore (up 2%) with margins of 18.8% standalone and 16.9% consolidated, and PAT came in at INR 10.3 crore. Management has received INR 80.55 crore in insurance claims with INR 268.27 crore still receivable, and the replacement Dahej plant is on track for next year. The Board approved a INR 200 crore NCD private placement to ensure liquidity during ongoing CAPEX. Key updates included founding Chairman Mr. Haridas Kanani retiring September 30, 2025 (to become Chairman Emeritus), with Mr. Anurag Surana taking over as Chairman. The Pakhajan Greenfield electrolyte facility has deployed INR 506 crore of the INR 1,500 crore CAPEX, and a new JV with Japan's Morita Chemical Industries (Neogen Morita New Materials) has been incorporated to produce lithium salts.
Shareholders can expect the second half of FY26 to be stronger, as Neogen Ionics revenue (targeted INR 300 crore run rate) is back-end loaded and dependent on cell-maker ramp-ups. Management maintained base business guidance of INR 825-875 crore and reaffirmed a 20% ROCE target at full utilization, signaling confidence in long-term profitability despite near-term operational disruptions. The NCD raise and pending insurance inflows should keep the balance sheet comfortable through the heavy CAPEX phase.